Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-phosphatidylserine monoclonal antibodies - Affitech/Avid Bioservices

Drug Profile

Research programme: anti-phosphatidylserine monoclonal antibodies - Affitech/Avid Bioservices

Alternative Names: 11.31; 1N11; 3J05; AT 004; AT 005; Fully human bavituximab; PGN 632; PGN 634; PGN 635

Latest Information Update: 28 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affitech A/S; Peregrine Pharmaceuticals
  • Developer Affitech A/S; Avid Bioservices; Peregrine Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Phosphatidylserine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Cancer; HIV infections; Lassa fever; Viral haemorrhagic fevers; Viral infections; Yersinia infections

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for research development in HIV-infections in USA (Parenteral)
  • 21 Apr 2018 Parmacodynamics data from preclinical trial in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 05 Jan 2018 Peregrine Pharmaceuticals is now called Avid Bioservices
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top